| Friday, November 3, 2023 10:30-14:30 Central European Time (CET) |
|
| Welcome Note Yuval Yaron, Israel |
|
| Sponsored symposium- Illumina Prenatal Genomic Sequencing: improving diagnostic yield and aiding clinical utility Mark Kilby, UK |
|
| Session 1: Advances in Prenatal Diagnosis | |
| The diagnostic yield of prenatal exome sequencing in structurally normal fetuses Hagit Daum, Israel |
|
| NGS Based newborn screening David Bick, UK |
|
| Somatic mutation causing megalencephaly Ritsuko Kimata Pooh, Japan |
|
| The use of Optical Genome Mapping in Prenatal Diagnosis Brynn Levy, USA |
|
| Session 2: Non-Invasive Prenatal testing | |
| TRIDENT2 results and conclusions Erik Sistermans, The Netherlands |
|
| The use of cfDNA to screen for monogenic conditions in low risk populations Neeta Vora, USA |
|
| Cell-Based Non-invasive Prentatal Testing – Is it still a Distant Star? Ripudaman Singh, Denmark |
|
| NIPT for sex chromosome abnormalities global practices and ethical implication Ida Vogel, Denmark |
|
| Saturday, November 4, 2023 10:30-14:30 Central European Time (CET) |
|
| Sponsored symposium- Revvity Moderator: Yuval Yaron, Israel From samples to outcomes, one Canadian laboratory’s experience with the Vanadis NIPT platform Jean Gekas, Canada The benefits and pitfalls of using PPV for NIPT clinical interpretation Lawrence Prensky, Revvity |
|
| Session 3: Preimplantation genetic testing (PGT) | |
| Ex Utero Embryogenesis: Naive Pluripotent Stem-cells-derived Embryoid Models (SEMs) Yaqub Hanna, Israel |
|
| Whole genome PGT for transmitted and de novo mutations, using whole genome sequencing (PGT-WGS) with GenomeScreen® Santiago Munne, Spain |
|
| How close are we to universal PGT Tony Gordon, UK |
|
| Pathways leading to segmental aneuploidy Joris Vermeesch, Belgium |
|
| Genetic Impacts on IVF Embryo Viability Rajiv McCoy, USA |
|
| Eliminating pathogenic genes: Gene editing (CRISPR) vs. PGT-M Avner Hershlag, USA |
|
| Congress summary and Highlights Yuval Yaron, Israel |
|